Vitrolife AB (publ) (VITR.ST)
SEK 214.4
(1.13%)
SEK 214.4
(1.13%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.39 Billion SEK | -20.24% |
| 2022 | 20.55 Billion SEK | 5.78% |
| 2021 | 19.42 Billion SEK | 742.87% |
| 2020 | 2.3 Billion SEK | 7.78% |
| 2019 | 2.13 Billion SEK | 25.99% |
| 2018 | 1.69 Billion SEK | 19.34% |
| 2017 | 1.42 Billion SEK | 13.75% |
| 2016 | 1.25 Billion SEK | 18.06% |
| 2015 | 1.05 Billion SEK | 8.92% |
| 2014 | 972.48 Million SEK | 99.36% |
| 2013 | 487.8 Million SEK | 5.54% |
| 2012 | 462.19 Million SEK | -0.98% |
| 2011 | 466.78 Million SEK | 8.71% |
| 2010 | 429.38 Million SEK | 19.5% |
| 2009 | 359.31 Million SEK | 4.86% |
| 2008 | 342.66 Million SEK | 14.43% |
| 2007 | 299.46 Million SEK | 10.49% |
| 2006 | 271.03 Million SEK | 28.23% |
| 2005 | 211.37 Million SEK | 13.92% |
| 2004 | 185.53 Million SEK | 0.84% |
| 2003 | 183.99 Million SEK | -2.4% |
| 2002 | 188.51 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 16.87 Billion SEK | 2.94% |
| 2024 Q3 | 16.88 Billion SEK | 0.19% |
| 2024 Q2 | 16.85 Billion SEK | -0.12% |
| 2023 FY | 16.39 Billion SEK | -20.24% |
| 2023 Q4 | 16.39 Billion SEK | -22.61% |
| 2023 Q3 | 21.18 Billion SEK | -2.16% |
| 2023 Q2 | 21.64 Billion SEK | 4.27% |
| 2023 Q1 | 20.76 Billion SEK | 1.03% |
| 2022 Q1 | 19.53 Billion SEK | 0.55% |
| 2022 Q4 | 20.55 Billion SEK | 1.71% |
| 2022 FY | 20.55 Billion SEK | 5.78% |
| 2022 Q3 | 20.2 Billion SEK | 1.5% |
| 2022 Q2 | 19.9 Billion SEK | 1.9% |
| 2021 Q2 | 2.51 Billion SEK | 0.65% |
| 2021 FY | 19.42 Billion SEK | 742.87% |
| 2021 Q1 | 2.49 Billion SEK | 8.35% |
| 2021 Q4 | 19.42 Billion SEK | 216.39% |
| 2021 Q3 | 6.14 Billion SEK | 144.29% |
| 2020 Q1 | 2.24 Billion SEK | 5.09% |
| 2020 Q4 | 2.3 Billion SEK | 2.21% |
| 2020 FY | 2.3 Billion SEK | 7.78% |
| 2020 Q2 | 2.2 Billion SEK | -1.97% |
| 2020 Q3 | 2.25 Billion SEK | 2.37% |
| 2019 Q2 | 1.95 Billion SEK | 3.86% |
| 2019 Q1 | 1.88 Billion SEK | 10.76% |
| 2019 FY | 2.13 Billion SEK | 25.99% |
| 2019 Q4 | 2.13 Billion SEK | 2.22% |
| 2019 Q3 | 2.09 Billion SEK | 7.15% |
| 2018 Q1 | 1.55 Billion SEK | 8.98% |
| 2018 Q2 | 1.56 Billion SEK | 1.05% |
| 2018 Q3 | 1.61 Billion SEK | 3.38% |
| 2018 Q4 | 1.69 Billion SEK | 4.83% |
| 2018 FY | 1.69 Billion SEK | 19.34% |
| 2017 FY | 1.42 Billion SEK | 13.75% |
| 2017 Q4 | 1.42 Billion SEK | 7.99% |
| 2017 Q3 | 1.31 Billion SEK | 1.1% |
| 2017 Q2 | 1.3 Billion SEK | 1.31% |
| 2017 Q1 | 1.28 Billion SEK | 2.85% |
| 2016 Q1 | 1.1 Billion SEK | 4.52% |
| 2016 Q4 | 1.25 Billion SEK | 5.14% |
| 2016 Q3 | 1.18 Billion SEK | 5.36% |
| 2016 Q2 | 1.12 Billion SEK | 1.96% |
| 2016 FY | 1.25 Billion SEK | 18.06% |
| 2015 Q1 | 960.44 Million SEK | -1.24% |
| 2015 Q4 | 1.05 Billion SEK | 6.66% |
| 2015 Q3 | 993.13 Million SEK | 3.75% |
| 2015 Q2 | 957.27 Million SEK | -0.33% |
| 2015 FY | 1.05 Billion SEK | 8.92% |
| 2014 Q3 | 554.34 Million SEK | 9.71% |
| 2014 Q4 | 972.48 Million SEK | 75.43% |
| 2014 Q2 | 505.26 Million SEK | 1.57% |
| 2014 Q1 | 497.44 Million SEK | 1.97% |
| 2014 FY | 972.48 Million SEK | 99.36% |
| 2013 Q4 | 487.8 Million SEK | 4.4% |
| 2013 Q2 | 479.56 Million SEK | 2.95% |
| 2013 Q1 | 465.84 Million SEK | 0.79% |
| 2013 Q3 | 467.23 Million SEK | -2.57% |
| 2013 FY | 487.8 Million SEK | 5.54% |
| 2012 Q1 | 473.88 Million SEK | 1.52% |
| 2012 Q4 | 462.19 Million SEK | -6.68% |
| 2012 FY | 462.19 Million SEK | -0.98% |
| 2012 Q2 | 501.47 Million SEK | 5.82% |
| 2012 Q3 | 495.29 Million SEK | -1.23% |
| 2011 Q3 | 463 Million SEK | 4.72% |
| 2011 Q1 | 436.47 Million SEK | 1.65% |
| 2011 Q2 | 442.13 Million SEK | 1.3% |
| 2011 FY | 466.78 Million SEK | 8.71% |
| 2011 Q4 | 466.78 Million SEK | 0.82% |
| 2010 FY | 429.38 Million SEK | 19.5% |
| 2010 Q4 | 429.38 Million SEK | 10.6% |
| 2010 Q3 | 388.25 Million SEK | -0.29% |
| 2010 Q2 | 389.39 Million SEK | 0.0% |
| 2009 Q4 | 359.31 Million SEK | 0.0% |
| 2009 FY | 359.31 Million SEK | 4.86% |
| 2008 FY | 342.66 Million SEK | 14.43% |
| 2007 FY | 299.46 Million SEK | 10.49% |
| 2006 FY | 271.03 Million SEK | 28.23% |
| 2005 FY | 211.37 Million SEK | 13.92% |
| 2004 FY | 185.53 Million SEK | 0.84% |
| 2003 FY | 183.99 Million SEK | -2.4% |
| 2002 FY | 188.51 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -25965.454% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | -398.601% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | -398.601% |
| Arcoma AB | 81.96 Million SEK | -19898.292% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | -2300.282% |
| BICO Group AB (publ) | 10.19 Billion SEK | -60.747% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | -2070.706% |
| CellaVision AB (publ) | 928.71 Million SEK | -1664.917% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -28294.976% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -74555.628% |
| C-Rad AB (publ) | 404 Million SEK | -3957.178% |
| Duearity AB (publ) | 15.14 Million SEK | -108134.284% |
| Dignitana AB (publ) | 44.83 Million SEK | -36461.754% |
| Episurf Medical AB (publ) | 104.3 Million SEK | -15615.244% |
| Getinge AB (publ) | 55.09 Billion SEK | 70.252% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | -15869.675% |
| Iconovo AB (publ) | 128.07 Million SEK | -12697.482% |
| Integrum AB (publ) | 164.85 Million SEK | -9842.428% |
| Luxbright AB (publ) | 40.68 Million SEK | -40185.933% |
| Mentice AB (publ) | 322.52 Million SEK | -4982.071% |
| OssDsign AB (publ) | 356.38 Million SEK | -4499.188% |
| Paxman AB (publ) | 167.12 Million SEK | -9707.629% |
| Promimic AB (publ) | 92.87 Million SEK | -17548.452% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -41878.692% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -25377.974% |
| ScandiDos AB (publ) | 81.47 Million SEK | -20018.321% |
| Sectra AB (publ) | 3.21 Billion SEK | -410.474% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | -1516.379% |
| Senzime AB (publ) | 433.54 Million SEK | -3680.718% |
| SpectraCure AB (publ) | 144.83 Million SEK | -11217.094% |
| Stille AB | 804.89 Million SEK | -1936.417% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | -646.535% |